in combination with chemotherapy (chemo) for HER2-positive breast cancer (BC): results from a phase 1 study. Cancer Res 2022; 82 (4_Suppl.): P2-13-07. 10.1158/1538-7445.SABCS21-P2-13-07
in combination with chemotherapy (chemo) for HER2-positive breast cancer (BC): results from a phase 1 study. Cancer Res 2022; 82 (4_Suppl.): P2-13-07. 10.1158/1538-7445.SABCS21-P2-13-07
曲妥珠单抗生物类似物:与新型研发的HER2靶向抗体不同,曲妥珠单抗生物类似物是由活细胞形成的生物制剂,具有与原产品相似的药代动力学和药效学特性。目前FDA批准了五种曲妥珠单抗生物类似物进入美国市场,其他药物正在开发中(见相关链接: https://www.fda.gov/dr...
Bedard, P. L. et al. Zanidatamab (ZW25), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) for HER2-positive breast cancer (BC): results from a phase 1 study. Cancer Res. 82 (Suppl. 4), Abstr. P2-13-07 (2022)....
[41]Janjigian YY, Kawazoe A, Bai Y, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial[J]. Lancet. 2023 Dec 9;402(10418):2197-2208. doi...
Keywords: Human epidermal growth factor receptor-2; Non-small cell lung cancer; Tyrosine kinase inhibitors; Anti‑ body-drugs conjugate; Immune checkpoint inhibitors 前言 肺癌是目前常见癌症类型之一,也是导致癌症 死亡的主要原因[1]. 肺癌根据组织学可分为两大类:小细胞肺癌(small cell lung cancer,SCLC...
L. et al. Zanidatamab (ZW25), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) for HER2-positive breast cancer (BC): results from a phase 1 study. Cancer Res. 82 (Suppl. 4), Abstr. P2-13-07 (2022). Article Google Scholar Geuijen, C. A. et al. ...
LBA53 Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): first results of a randomized, double-blind, phase III study. Ann. Oncol. 32, S1331 (2021). Article Google Scholar Zhang, Z...
HER2突变(即ERBB2突变)在非鳞非小细胞肺癌(NSCLC)患者的发生率约为3%。其中,约90%的HER2突变类型为20号外显子插入突变(Exon 20ins)。
[12] Janjigian Y Y , Kawazoe A , Yaez P , et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer[J]. Nature, 2021, 600. [13] XU JM, JIANG HP,PAN YY,et al.Sintilimab plus chemotheray(c...